You are here

Article info

Article menu
Case report
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report

Authors

  • Dan Li Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Yimei Que Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Shengnan Ding Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Guang Hu Nanjing IASO Biotherapeutics Ltd, Nanjing, Jiangsu, China PubMed articlesGoogle scholar articles
  • Wen Wang Nanjing IASO Biotherapeutics Ltd, Nanjing, Jiangsu, China PubMed articlesGoogle scholar articles
  • Xia Mao Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Ying Wang Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Chunrui Li Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Liang Huang Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Jianfeng Zhou Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Wei Zhang Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles
  • Min Xiao Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Immunotherapy Research, Wuhan, Hubei, China PubMed articlesGoogle scholar articles

Citation

Li D, Que Y, Ding S, et al
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
Journal for ImmunoTherapy of Cancer 2022;10:e005403. doi: 10.1136/jitc-2022-005403
Online issue publication 
September 22, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.